Diane Ling, MD

Assistant Professor of Clinical Radiation Oncology

Director of Quality and Safety for Keck Medicine

Image of Diane Ling, MD
Is this your profile? Click to edit

Overview

Dr. Diane C. Ling is an Assistant Professor of Clinical Radiation Oncology at the Keck School of Medicine. She joined the faculty in August, 2020. Her clinical practice is located at USC Norris Cancer Hospital.

She grew up in the Bay Area and Sacramento, and graduated from the University of California, Berkeley with a bachelor’s degree in Molecular and Cell Biology. She earned her medical doctorate degree at the University of Pittsburgh School of Medicine, where she was inducted into the Alpha Omega Alpha Honor Medical Society. She completed her residency at the University of Pittsburgh Medical Center, Hillman Cancer Center in Pittsburgh, PA, where she was chief resident.

Dr. Ling specializes in treating gastrointestinal and breast cancers. She has extensive experience with modern treatment techniques including intensity-modulated radiation therapy, volumetric-modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, and motion management techniques. Her work has resulted in numerous publications, presentations at national meetings, and conference awards, including the Young Oncologist Essay Award as well as the James D. Cox Award of Scientific Merit from the American Radium Society.

Languages Spoken: English, Mandarin.

Publications

  • Radiotherapy for the Treatment of Peyronie Disease (Induratio Penis Plastica): An American Radium Society (ARS) Appropriate Use Criteria (AUC). Am J Clin Oncol. 2026 Sep 15.. View in PubMed
  • Low Dose Radiotherapy for the Treatment of Inflammatory Periarticular Disorders: An American Radium Society (ARS) Appropriate Use Criteria (AUC). Am J Clin Oncol. 2026 Sep 07.. View in PubMed
  • The Role of Adjuvant Radiotherapy for the Prevention of Recurrent Hypertrophic Scars/Keloids: An American Radium Society (ARS) Appropriate Use Criteria (AUC). Am J Clin Oncol. 2026 Aug 28.. View in PubMed
  • Executive Summary of the American Radium Society Appropriate Use Criteria for a Multidisciplinary Treatment Approach to the Management of Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma. Int J Radiat Oncol Biol Phys. 2026 Aug 25.. View in PubMed
  • Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Adjuvant Therapy for Resected Adenocarcinoma of the Pancreas. Am J Clin Oncol. 2026 Aug 20.. View in PubMed
  • Executive summary of American Radium Society Appropriate Use Criteria for the treatment of locoregionally recurrent rectal cancer. Cancer. 2026 Jun 15; 132(12):e70464.. View in PubMed
  • Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848. J Clin Oncol. 2026 Aug 20; 44(24):2316-2328.. View in PubMed
  • Impact of Tamoxifen Only After Lumpectomy for “Good-Risk” Duct Carcinoma In Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials. Int J Radiat Oncol Biol Phys. 2026 May 09.. View in PubMed
  • Executive Summary of the American Radium Society Appropriate Use Criteria for Selective Use of Pelvic Radiation Therapy in Locally Advanced Rectal Cancer: A Consensus Statement. Int J Radiat Oncol Biol Phys. 2026 Mar 25.. View in PubMed
  • Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Locoregional Gastric Adenocarcinoma. Am J Clin Oncol. 2026 Feb 20.. View in PubMed